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Summary
 
B cell antigen receptor (BCR) cross-linking activates three distinct families of nonreceptor pro-
tein tyrosine kinases (PTKs): src-family kinases, Syk, and Btk; these PTKs are responsible for
initiating downstream events. BCR cross-linking in the chicken DT40 B cell line also activates
three distinct mitogen-activated protein kinases (MAPKs): extracellular signal–regulated kinase
(ERK)2, c-jun NH
 
2
 
-terminal kinase (JNK)1, and p38 MAPK. To dissect the functional roles
of these PTKs in MAPK signaling, activation of MAPKs was examined in various PTK-defi-
cient DT40 cells. BCR-mediated activation of ERK2, although maintained in Lyn-deficient
cells, was abolished in Syk-deficient cells and partially inhibited in Btk-deficient cells, indicat-
ing that BCR-mediated ERK2 activation requires Syk and that sustained ERK2 activation re-
quires Btk. BCR-mediated JNK1 activation was maintained in Lyn-deficient cells but abol-
ished in both Syk- and Btk-deficient cells, suggesting that JNK1 is activated via a Syk- and
Btk-dependent pathway. Consistent with this, BCR-mediated JNK1 activation was dependent
on intracellular calcium and phorbol myristate acetate–sensitive protein kinase Cs. In contrast,
BCR-mediated p38 MAPK activation was detected in all three PTK-deficient cells, suggesting
that no single PTK is essential. However, BCR-mediated p38 MAPK activation was abolished
in Lyn/Syk double deficient cells, demonstrating that either Lyn or Syk alone may be sufficient
to activate p38 MAPK. Our data show that BCR-mediated MAPK activation is regulated at
the level of the PTKs.
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B
 
cells recognize and respond to foreign antigens
through their surface-expressed B cell antigen receptor
(BCR)
 
1
 
 complexes composed of antigen-binding mem-
brane Ig and disulfide-linked heterodimer Ig
 
a
 
/Ig
 
b
 
, which
are the signaling subunits of the BCR (1, 2). The signaling
cascade initiated by Ig
 
a
 
/Ig
 
b
 
 after BCR cross-linking can
promote different biological outcomes, depending on the
differentiation stage of the B cell and the nature of addi-
tional signals received by the cell. Immature B cells become
anergized or undergo apoptosis upon antigen binding,
whereas mature B cells enter the cell cycle after BCR liga-
tion and can then be induced by other signals to differenti-
ate into antibody-secreting plasma cells. A key early event
of BCR signaling is the activation of protein tyrosine ki-
nases (PTKs), which initiates most if not all of the subse-
quent signaling events (3, 4). Since the BCR has no intrin-
sic PTK activation, for signal transduction it uses three
distinct families of nonreceptor cytoplasmic PTKs: Lyn,
Blk, Fyn, Lck, and Fgr of the Src family, Syk of the Syk/
ZAP-70 family, and Btk of the Tec family (5–8).
Mitogen-activated protein kinases (MAPKs) play a cen-
tral role in transducing extracellular signals from the cytosol
to the nucleus (9, 10). Three structurally related MAPK
subfamilies have been identified in mammalian cells: the
p42 and p44 kinases (extracellular signal-regulated kinases
[ERKs]; references 11, 12), the c-jun NH
 
2
 
-terminal kinases
 
1
 
Abbreviations used in this paper:
 
 ATF, activating transcription factor; BAPTA-
AM, the acetoxymethyl ester of bis-(
 
o
 
-aminophenoxy) ethane-N,N,N
 
9
 
,
N
 
9
 
-tetraacetic acid; BCR, B cell antigen receptor; [Ca
 
2
 
1
 
]
 
i
 
, intracellular cyto-
plasmic free Ca
 
2
 
1
 
 concentration; ERK, extracellular signal-regulated kinase;
GST, glutathione S-transferase; JNK, c-jun NH
 
2
 
-terminal kinase; MAPK,
mitogen-activated protein kinase; MBP, myelin basic protein; PKC, protein
kinase C; PLC-
 
g
 
2, phospholipase C-
 
g
 
2; PTK, protein tyrosine kinase.
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(JNKs)/stress activated protein kinases (SAPKs) (13–15),
and the p38 MAPK family (16, 17). Different patterns of
activation of MAPKs may well direct B cells to different
cell fates such as proliferation, differentiation, and apopto-
sis. In a human B cell line B104, activation of JNK and p38
MAPK, but not ERK, is correlated with induction of apop-
tosis by surface IgM stimulation (18). Both ERKs and
JNK1 are activated during positive signaling in naive B
cells, whereas only ERKs but not JNK1 are activated in
tolerant cells upon BCR stimulation by the same ligand
(19). However, the mechanisms that lead to the activation
of these distinct MAPKs have not been elucidated.
The chicken DT40 B cell line expresses only specific
members of the Src, Syk/ZAP-70, and Tec PTK families:
Lyn of the Src-family, Syk of the Syk/ZAP70 family, and
Btk of the Tec family (20, 21). Using Syk-, Lyn-, and Btk-
deficient DT40 cells, we investigated the participation of
PTKs in MAPK signaling. We report that BCR cross-link-
ing in DT40 cells activates three distinct MAPKs: ERK2,
JNK1, and p38 MAPK. Whereas Syk and Btk regulate the
activation of ERK2 and JNK1, Lyn does not. Furthermore,
either Syk or Lyn is sufficient for the activation of p38
MAPK upon BCR ligation, whereas Btk does not appear
to regulate this MAPK family member. Thus, the BCR
uses different PTKs to regulate members of distinct
MAPKs in B cells.
 
Materials and Methods
 
Reagents.
 
The mouse anti–chicken IgM mAb M4 was pre-
pared as previously described (22); PMA, ionomycin, and 4
 
a
 
-
phorbol were purchased from Calbiochem, Inc. (San Diego,
CA). Thapsigargin was purchased from Sigma Chemical Co. (St.
Louis, MO). Polyclonal rabbit antisera against JNK1 (C-17),
ERK2 (C-14), ERK1 (C-16), and p38 MAPK (C-20) were ob-
tained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Polyclonal rabbit antiphospho-MAPK (ERK2) was purchased
from Promega Corp. (Madison, WI). Purified mouse anti–human
JNK1 monoclonal antibody was purchased from PharMingen
(San Diego, CA). Myelin basic protein (MBP) was purchased from
Upstate Biotechnology, Inc. (Lake Placid, NY). Glutathione
S-transferase (GST)-c-jun (5–89) and GST-activating transcription
factor (ATF)2 were expressed in 
 
Escherichia coli
 
, and the fusion pro-
teins were purified as previously described (23). Protein A–sepharose
was obtained from Amersham Pharmacia Biotech, Inc. (Piscataway,
NJ). BAPTA-AM [the acetoxymethyl ester of bis-(
 
o
 
-aminophen-
oxy) ethane-N,N,N
 
9
 
,N
 
9
 
-tetraacetic acid] and Pluronic F-127 were
purchased from Molecular Probes, Inc. (Eugene, OR).
 
Cell Lines.
 
The generation of Syk-, Lyn-, and Btk-deficient,
and Lyn/Syk double deficient, DT40 cell lines was carried out as
previously described (20, 21). DT40 wild-type and PTK-defi-
cient cell lines were cultured in RPMI 1640 medium supple-
mented with 10% heat-inactivated FCS, 2 mM glutamine, 10 U/ml
penicillin, 10 
 
m
 
g/ml streptomycin, 1 mM pyruvate and nones-
sential amino acids, 50 
 
m
 
M mercaptoethanol, and 1% heat-inacti-
vated chicken serum. The cells were maintained below a density
of 3 
 
3 
 
10
 
6
 
 cells/ml.
 
Measurement of Intracellular Free Calcium.
 
Cells (2.5 
 
3 
 
10
 
7
 
 cell
per sample) were collected and resuspended to 10
 
7
 
 cells/ml in
fresh complete RPMI 1640 medium. After incubation at 37
 
8
 
C
for 15 min, indo-1/AM (7 
 
m
 
g/ml final concentration) was added,
and the cells were incubated for a further 45 min with resuspen-
sion every 15 min. The cells were subsequently centrifuged and
resuspended in complete RPMI 1640 medium at 2 
 
3 
 
10
 
6
 
 cells/ml.
The fluorescence intensity of intracellular indo-1 was monitored
and analyzed using a FACStar
 
Ò
 
 
 
plus flow cytometer (Becton
Dickinson, Mountain View, CA) as previously described (24).
 
Western Blot Analysis.
 
Unstimulated cells or anti-IgM stimu-
lated cells (5 
 
3 
 
10
 
6
 
 cells per sample) were lysed in 100 
 
m
 
l RIPA
lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 10 mM
Na
 
4
 
P
 
2
 
O
 
7
 
, 25 mM sodium 
 
b
 
-glycerophosphate, 1 mM EDTA, 1%
(wt/vol) NP-40, 0.5% (wt/vol) sodium deoxycholate, 0.1% (wt/
vol) SDS, 1 mM PMSF, 1 mM Na
 
3
 
VO
 
4
 
, 10 
 
m
 
M E-64, 1 
 
m
 
g/ml
pepstatin, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin). After incu-
bation on ice for 15 min, cell lysates were centrifuged at 16,000 
 
g
 
for 15 min at 4
 
8
 
C. Lysates were subsequently denatured in an
equal volume of 2
 
3
 
 SDS sample buffer, resolved by 10% SDS-
PAGE and electrotransferred to nitrocellulose membranes in
non-SDS-containing transfer buffer (25 mM Tris, 0.2 M glycine,
20% methanol, pH 8.5). Western blotting was performed with
the following primary antibodies and accompanying dilutions:
antiphospho ERK2 (1:20,000), anti-MAPK (ERK1 or ERK2,
1:2,000), anti-p38 (1:1,000), and mouse monoclonal anti-JNK1
(1:500) followed by 1:2,000 anti–rabbit or anti–mouse horserad-
ish peroxidase–conjugated IgG (Santa Cruz Biotechnology, Inc.)
and were developed with an ECL Western blotting kit (Amer-
sham Corp., Arlington Heights, IL).
 
Immunoprecipitation and In Vitro Kinase Assay.
 
For JNK1,
ERK2,  and p38 MAPK in vitro kinase assays, cells (5–10 
 
3 
 
10
 
6
 
cells per sample) were resuspended in complete RPMI 1640 me-
dium to a density of 2 
 
3 
 
10
 
6 
 
cells/ml and stimulated with either
anti-IgM (10 
 
m
 
g/ml) or PMA (50 ng/ml) with or without iono-
mycin (250 ng/ml) for the indicated times. Incubations were ter-
minated by addition of 10 vol of ice-cold PBS and were subse-
quently centrifuged at 500 
 
g
 
 for 8 min at 4
 
8
 
C. The supernatants
were aspirated and cells were lysed by resuspension in 0.5 ml
RIPA lysis buffer. After incubation on ice for 15 min, the cell ly-
sates were centrifuged at 16,000 
 
g
 
 for 15 min at 4
 
8
 
C. For JNK1
and ERK2 in vitro kinase assays, supernatants were added to 20 
 
m
 
l
packed protein A–sepharose beads and 0.5 
 
m
 
g polyclonal rabbit
anti-JNK or anti-ERK2 antibody, followed by overnight incuba-
tion at 4
 
8
 
C. For p38 MAPK assays, the lysates were first added to
1 
 
m
 
g polyclonal rabbit anti-p38 MAPK antiserum with an addi-
tional 0.1% SDS. After constant mixing by inversion for 3 h or
overnight at 4
 
8
 
C, the mixtures were added to 20 
 
m
 
l packed pro-
tein A-sepharose beads for another 1 h. The immune complexes
were pelleted at 4
 
8
 
C by centrifugation at 16,000 
 
g
 
 for 10 min.
The beads were washed twice each with (
 
a
 
) 1 ml of RIPA buffer
with 0.1 mM Na
 
3
 
VO
 
4 
 
and (
 
b
 
) 1 ml of p38 MAPK assay buffer (25
mM Hepes, pH 7.4, 25 mM sodium 
 
b
 
-glycerophosphate, 25 mM
MgCl
 
2
 
, 2 mM dithiothreitol, and 0.1 mM Na
 
3
 
VO
 
4
 
). The pellets
were resuspended to 90 
 
m
 
l p38 MAPK assay buffer with 20 
 
m
 
M
ATP containing 10 
 
m
 
Ci 
 
g
 
-[
 
32
 
P]ATP and 50 
 
m
 
g/ml substrate
(MBP for ERK2, GST–c-jun for JNK1, or GST-ATF2 for p38
MAPK). After incubation for 20 min at 30
 
8
 
C with mixing every
2 min, the reactions were terminated by adding 45 
 
m
 
l 2
 
3
 
 SDS
sample buffer. After boiling for 5 min followed by brief centrifu-
gation, samples were resolved by SDS-PAGE (12% for JNK1 and
p38 MAPK assays and 14 or 12% for ERK2 assays). The gels were
stained for 30 min with 40% methanol, 10% acetic acid, and
0.005% Coomassie brilliant blue G-250, destained for 30 min
with 40% methanol, 10% acetic acid, and 5% glycerol, and dried
before autoradiography at 
 
2
 
70
 
8
 
C for various times. 
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Results
 
BCR-mediated Activation of ERK2 Requires Syk and Btk.
 
Since engagement of the BCR complex strongly activates
p42 ERK2 in other B cell lines and in normal B cells (25,
26), we tested whether BCR cross-linking in DT40 B cells
could also lead to ERK2 activation. In vitro kinase assays
were performed with anti-ERK2 immunoprecipitates to
assess induction of ERK2 activation. Consistent with pre-
vious studies, ERK2 activation was detected shortly after
BCR cross-linking, with a maximal fourfold activation
compared with unstimulated cells evident at 2 min and sus-
tained for at least 15 min (Fig. 1 
 
A
 
). To determine the PTK
requirement for BCR-mediated ERK2 activation, we
compared ERK2 activation in wild-type versus mutant
DT40 cell lines deficient in Lyn, Syk, or Btk that expressed
comparable levels of surface IgM (20, 21). BCR-mediated
ERK2 activation was completely abolished in Syk-deficient
cells even though ERK2 was activated by PMA to a similar
extent compared with wild-type DT40 cells (Fig. 1 
 
A
 
);
thus, Syk is required for BCR-mediated ERK2 activation.
In contrast, BCR-mediated ERK2 activation was largely
maintained in Lyn-deficient cells with a maximal threefold
activation at 5 min (Fig. 1 
 
A
 
), indicating that ERK2 can be
activated via the BCR in the absence of Lyn. In contrast to
either Syk- or Lyn-deficient cell lines, BCR ligation in
Btk-deficient cells led to a transient and weak ERK2 acti-
vation (less than twofold), suggesting that a Btk-indepen-
dent ERK2 activation pathway exists and that Btk is re-
quired for sustained ERK2 activation (Fig. 1 
 
A
 
).
As an alternative assay for ERK2 activation, we mea-
sured the phosphorylation of ERK2 using Western blotting
and a phospho-MAPK antiserum, which only detected
phosphorylated ERK2 in DT40 cells (Fig. 1 
 
B
 
). Consistent
with our in vitro kinase assays, phosphorylated ERK2 was
detected in DT40 cells between 2 and 15 min after anti-
IgM stimulation (Fig. 1 
 
B
 
). No BCR-mediated phosphory-
lation of ERK2 was detected in Syk-deficient cells; in Lyn-
deficient cells phosphorylation of ERK2 was comparable
with wild-type DT40 cells, whereas weak and transient
ERK2 phosphorylation was observed in Btk-deficient cells
(Fig. 1 
 
B
 
). In summary, BCR-mediated ERK2 activation re-
quires Syk, whereas sustained ERK2 activation requires Btk.
 
BCR-mediated JNK1 Activation Requires both Syk and Btk
but not Lyn.
 
JNKs are activated preferentially by a variety
of extracellular stresses, and in most circumstances they are
activated through a different pathway from ERKs (10, 13–
15). BCR cross-linking also led to JNK1 activation in
DT40 cells as determined by its ability to phosphorylate
GST–c-jun. JNK1 was maximally activated (fourfold) be-
tween 10 and 15 min and then decreased by 30 min (Fig. 2
 
A
 
). To test whether BCR-mediated JNK1 activation has
the same PTK requirement as BCR-mediated ERK2 acti-
vation, we compared the ability of the BCR to activate
JNK1 in Syk-, Lyn-, and Btk-deficient DT40 cells. The
expression levels of JNK1 were not affected either by the
deletion of various PTK genes or anti-IgM stimulation
(Fig. 2 
 
B
 
). BCR-mediated JNK1 activation was maintained
in Lyn-deficient cells with a maximal fivefold JNK1 activa-
tion at 15 min (Fig. 2 A), suggesting that Lyn was not es-
sential for BCR-mediated JNK1 activation. However, in
both Syk- and Btk-deficient cells, the anti-IgM–induced
JNK1 activation was completely abolished (Fig. 2 A), indi-
cating that both Syk and Btk were essential for JNK1 acti-
vation. Thus, BCR-mediated JNK1 activation requires
both Syk and Btk but not Lyn.
BCR-mediated p38 MAPK Activation Occurs via a Different
Pathway from both ERK2 and JNK1. As a relatively new
member of the mammalian MAPKs, p38 MAPK has both a
different substrate specificity and different upstream activat-
ing kinases (MKKs) and appears to have a distinct transduc-
ing pathway and function (9, 10, 16, 17). p38 MAPK acti-
vation was examined by the ability of anti-p38 MAPK
immunoprecipitates to phosphorylate GST-ATF2. p38
MAPK reached a maximal fourfold activation at 15 min af-
ter anti-IgM stimulation, and, distinct from both ERK2
and JNK1 activation, persisted for at least 12 h (Fig. 3 A
and data not shown). To investigate whether p38 MAPK
Figure 1. ERK2 is activated after anti-IgM stim-
ulation in DT40 wild-type, Lyn-, and Btk-deficient
cells but not in Syk-deficient cells. (A) Cells (5 3 106
per sample) were stimulated with either anti-IgM
mAb M4 (5 mg/ml) for 0–45 min or PMA (50 ng/
ml) for 5 min, and cell lysates were immunoprecip-
itated with polyclonal anti-ERK2 antiserum (0.5
mg per sample). In vitro kinase assays were per-
formed on the immune complexes using MBP (50
mg/ml) as a substrate; kinase reaction products were
resolved by 14% SDS-PAGE, and their activation
was quantified by autoradiography and scanning
densitometry. MBP appeared as two separated
bands under these conditions, reflecting some degradation. One of three similar independent experiments is shown. Note that the ERK2 activation after
BCR engagement for 2 min in Lyn-deficient cells was atypically lower than that of DT40 wild-type cells but was similar to that of DT40 wild-type cells
in two other experiments. (B) Phosphorylation of ERKs in wild-type and various PTK-deficient DT40 cells. Cells (5 3 106 per sample) were stimulated
with anti-IgM mAb M4 (10 mg/ml) for 0–15 min. Cell lysates (equal to 106 per sample) were subsequently analyzed by immunoblotting with anti-phos-
pho-MAPK (top) or anti-ERK1 (bottom) Abs. The anti-ERK1 antibody recognized both ERK1 and ERK2, whereas the anti-phospho-MAPK (ERK2)
only detected phosphorylated ERK2 in these DT40 cells. The anti-ERK2 antibody we used for both ERK2 immunoprecipitation and in vitro kinase as-
says recognized only ERK2 not ERK1 (data not shown).1300 Differential Activation of Distinct MAP Kinases via the B Cell Receptor
has different requirements for upstream PTKs, we exam-
ined p38 MAPK activation in various PTK-deficient DT40
cells. There was no significant difference in p38 MAPK ex-
pression levels between the parental DT40 cells and various
PTK-deficient DT40 cells including the Lyn/Syk double
mutant cells (Fig. 3 B). In addition, the recovery of p38
MAPK after immunoprecipitation was also not significantly
different in DT40 wild-type and mutant cell lines (data not
shown). To our surprise, BCR-mediated p38 MAPK acti-
vation in Lyn-deficient cells (sixfold maximal activation),
Syk-deficient cells (threefold), and Btk-deficient cells
(threefold) was similar to that in wild-type DT40 cells (Fig.
3 A). The fold activations of p38 MAPK in Syk- and Btk-
deficient cells were lower in part because these cells had a
higher basal level of p38 MAPK activation (Fig. 3 A).
Thus, these data suggest that none of these PTKs alone is
essential for the BCR to activate p38 MAPK. Previous
studies have shown that both Lyn and Syk associate with
the BCR and account for most of the initial tyrosine phos-
phorylation including activation of Btk (21). Our data sug-
gested either that there was another PTK required for p38
MAPK activation, or alternatively that Syk and Lyn had a
redundant role in BCR-mediated p38 MAPK activation.
To test these possibilities, a Lyn/Syk double deficient
DT40 cell line was examined. BCR-mediated p38 MAPK
activation was lost in Lyn/Syk double deficient cells (Fig. 3
A), indicating that either Lyn or Syk was sufficient for
BCR-mediated p38 MAPK activation.
Activation of JNK1, but not ERK2 and p38 MAPK, via the
BCR Is Dependent on Intracellular Calcium. Anti-IgM stim-
ulation leads to a rapid increase of intracellular calcium
[Ca21]i composed of both Ca21 release from intracellular
pools and extracellular calcium influx (27). Previous studies
have demonstrated that loss of either Btk or Syk but not
Lyn resulted in abrogation of calcium mobilization upon
BCR cross-linking of DT40 cells (20, 21). Since the pat-
tern of BCR-mediated JNK1 activation correlated pre-
cisely with that of BCR-mediated calcium mobilization,
Figure 2. BCR-induced JNK1
activation requires both Syk and
Btk. (A) Activation of JNK1 in
wild-type and PTK-deficient
DT40 cells. Cells (5 3 106/sam-
ple) were stimulated with 5 mg/
ml anti–chicken IgM mAb M4
for 0–60 min or with PMA (50
ng/ml) and ionomycin (250 ng/
ml) for 10 min at 378C. Cells
were then lysed in RIPA buffer
and immunoprecipitated with
rabbit polyclonal anti-JNK1 anti-
serum (0.5 mg/sample). In vitro
kinase assays were performed with
GST–c-jun as a specific exogenous substrate; kinase reaction products were resolved by 12% SDS-PAGE, and their activation was quantified by autoradi-
ography and scanning densitometry. (B) Western blot analysis of JNK1 protein expression. DT40 cells were incubated with PMA (100 ng/ml), the inac-
tive derivative 4a-phorbol (100 ng/ml) or DMSO solvent vehicle control for 24 h before anti-IgM stimulation. Cell lysates (equal to 106/sample) were
denatured in SDS sample buffer, resolved by 10% SDS-PAGE, and subsequently were analyzed by Western blot analysis using a mouse anti–human JNK1
monoclonal antibody.
Figure 3. Either Lyn or Syk is sufficient
for BCR-mediated p38 MAPK activation.
(A) BCR-mediated p38 MAPK activation
was only abolished in Lyn/syk double defi-
cient cells. Cells (5 3 106 per sample) were
stimulated with 10 mg/ml anti–chicken IgM
mAb M4 for 0–60 min or with PMA (100
ng/ml) for 10 min at 378C. Cells were then
lysed in RIPA lysis buffer and immunoprecip-
itated with polyclonal anti-p38 MAPK antise-
rum (1 mg/sample) in the presence of an ad-
ditional 0.1% SDS. In vitro kinase assays
were performed using GST-ATF2 as a spe-
cific exogenous substrate and analyzed as de-
scribed in the legend to Fig. 2 A. (B) West-
ern blot analysis of p38 MAPK expression.
Cell lysates were prepared as described in the
legend to Fig. 2 B. The lysates (equal to 106/
sample) were resolved by 10% SDS-PAGE
and subsequently were analyzed by Western
blot analysis using a polyclonal anti-p38
MAPK antiserum.1301 Jiang et al.
we hypothesized that a calcium signal may modulate BCR-
mediated JNK1 activation. Furthermore, we could activate
JNK1 only with a combination of both ionomycin and
PMA (Fig. 2 A and data not shown), also supporting the
idea that a calcium signal was required for BCR-mediated
JNK1 activation. To define the requirement for calcium in
BCR-mediated JNK1 activation and specifically determine
whether intracellular or extracellular calcium was required,
cells were treated with either BAPTA-AM, a cell perme-
able calcium chelator, or EGTA, which chelates extracellu-
lar calcium before anti-IgM stimulation. The concentra-
tions of BAPTA-AM and EGTA were titrated to prevent
calcium release and extracellular calcium influx, respec-
tively (data not shown). BAPTA-AM pretreatment com-
pletely blocked BCR-induced JNK1 activation, whereas
EGTA pretreatment did not (Fig. 4 A), suggesting that
BCR-mediated JNK1 activation is dependent on intracel-
lular rather than extracellular calcium. We also asked
whether a calcium signal alone was sufficient for BCR-
mediated JNK1 activation. To directly address this ques-
tion, we pretreated DT40 mutant cells with thapsigargin, a
pharmacological reagent that prevents reuptake of intracel-
lular calcium into storage vesicles and thus mimics the
receptor-dependent increase of [Ca21]i while bypassing
phosphatidylinositol 4,5-bisphosphate hydrolysis (28). The
concentrations of thapsigargin were carefully titrated to
give a similar peak calcium signal as anti-IgM stimulation
(data not shown). JNK1 activation after BCR ligation was
not reconstituted in either Syk- or Btk-deficient DT40
cells (Fig. 4 B), indicating that a calcium signal alone was
not sufficient to activate JNK1. Other BCR-mediated sig-
nals, which require Syk and/or Btk, are also needed for
JNK1 activation.
Since partial BCR-mediated ERK2 activation was de-
tectable in Btk-deficient DT40 cells (Fig. 1), which are in-
capable of calcium mobilization after BCR ligation (21), it
seemed unlikely that BCR-mediated ERK2 activation was
calcium dependent. Indeed, pretreatment of DT40 cells
with either BAPTA-AM or EGTA did not block BCR-
mediated ERK2 activation (Fig. 4 A), indicating that a
BCR-mediated calcium signal was not required for ERK2
activation.
Both Syk- and Btk-deficient DT40 cells maintained the
ability to activate p38 MAPK via the BCR, suggesting that
BCR-mediated p38 MAPK activation was independent of
calcium. Indeed, neither BAPTA-AM nor EGTA pretreat-
ment blocked BCR-mediated p38 MAPK activation, show-
ing that BCR-mediated p38 MAPK activation was inde-
pendent of calcium (Fig. 4 A). Furthermore, BAPTA-AM
alone activated p38 MAPK (Fig. 4 A). Together with the
observation that the Btk- and Syk-deficient DT40 cells,
two mutants that lose their ability to mobilize calcium
upon BCR ligation, also exhibited higher basal levels of
p38 MAPK activation (Fig. 3), our results suggest that free
calcium may play a negative role in p38 MAPK activation.
BCR-induced Activation of ERK2 and JNK1 Is, but p38
MAPK Is Not, PKC Dependent. PMA treatment of wild-
type DT40 cells leads to p38 MAPK and ERK2 activation,
whereas both PMA and ionomycin are required for JNK1
activation (Fig. 1–3). Since both BCR cross-linking and
PMA treatment lead to PKC activation, it was interesting
to examine the role of PKCs in BCR-mediated MAPK
signaling.
DT40 cells were pretreated for 24 h with PMA (which
leads to depletion of PMA-dependent PKCs), an inactive
derivative of PMA, 4a-phorbol, or medium, before stimu-
lation with either anti-IgM or PMA. ERK2, JNK1, or p38
MAPK activation of the cells was then analyzed by in vitro
kinase assays. Neither PMA nor 4a-phorbol pretreatment of
DT40 cells had a significant effect on the expression levels
Figure 4. BCR-mediated ERK2, JNK1, and p38 MAPK activation have different requirements of calcium. (A) Anti-IgM–induced activation of
JNK1, but not of ERK2 and p38 MAPK, is dependent on intracellular calcium. Cells were preincubated with BAPTA-AM (10 mM) for 10 min or
EGTA (2 mM) for 30 min and then stimulated with anti-IgM mAb M4 (10 mg/ml). The concentrations of BAPTA-AM and EGTA were titrated to pre-
vent calcium release or extracellular calcium influx, respectively (data not shown). In vitro kinase assays were performed to measure the activation of
ERK2, JNK1 and p38 MAPK as described in the legends to Figs. 1–3, except that 12% SDS-PAGE was used for all these assays. The times of stimulation
of cells were as follows: ERK2, PMA for 5 min or anti-IgM for 2 min; JNK1, PMA and ionomycin or anti-IgM for 10 min; and p38 MAPK, PMA for
10 min or anti-IgM for 15 min. (B) A calcium signal is not sufficient for anti-IgM–induced JNK1 activation. Btk- and Syk-deficient cells were pre-incu-
bated with thapsigargin (10 nM) for 5 min and then stimulated with anti-IgM mAb M4 (10 mg/ml) or incubated with thapsigargin alone for the indicated
times. JNK1 activation was quantified by in vitro kinase assays as described in the legend to Fig. 2 A.1302 Differential Activation of Distinct MAP Kinases via the B Cell Receptor
of JNK1, p38 MAPK, and ERK2 (Figs. 2 B and 3 B and
data not shown). BCR ligation did not significantly in-
crease ERK2 activation above basal levels in PKC-depleted
cells (Fig. 5 A), suggesting that BCR-mediated ERK2 acti-
vation is dependent on PMA-depletable PKCs. JNK1 acti-
vation was also strongly decreased in PKC-depleted cells (Fig.
5 B), suggesting that PMA-depletable PKCs are required in
addition to a calcium signal (Fig. 4) for BCR-mediated
JNK1 activation. The requirement of both a calcium signal
and PKC activation is consistent with the observation that
only a combination of PMA and ionomycin, but not PMA
or ionomycin alone, could lead to significant JNK1 activa-
tion in DT40 cells (Fig. 5 B and data not shown). For
p38 MAPK, significant BCR-dependent activation (greater
than threefold increase) was still observed in PKC-depleted
cells (Fig. 5 C), suggesting that BCR-mediated p38 MAPK
activation is largely independent of PMA-depletable PKCs.
However, our results cannot rule out the participation of
other PMA-insensitive PKCs such as the atypical PKCz in
BCR-mediated p38 MAPK activation.
Discussion
In this report, we show that each of the three major
mammalian MAPK family members activated through the
BCR requires a different set of upstream protein tyrosine
kinases (Figs. 1–3 and 6).
Although it has been reported that ERKs are activated
upon anti-IgM stimulation via a Ras/Raf-1/MEK signal-
ing pathway (26, 29), the participation of proximal PTKs in
BCR-mediated MAPK activation is not well understood.
Our data demonstrate that Syk but not Lyn is absolutely es-
sential for BCR-mediated activation of ERK2 (Fig. 1).
Supporting this notion, recent studies using the Lck-nega-
tive JCaM1.6 variant of the Jurkat T cell line have shown
that Syk enabled the TCR to cause a full activation of
ERKs in the absence of the Src family kinase Lck (30). In
contrast, BCR-mediated ERK2 activation is only partially
dependent on Btk, suggesting that Btk has a regulatory role
rather than being an essential component in the ERK2 sig-
naling pathway. This possibility is also supported by the
fact that Syk is essential for phosphorylation of PLC-g2,
whereas the loss of Btk only reduces PLC-g2 phosphoryla-
tion (20, 21). Previous studies suggest that BCR-mediated
activation of Ras and PKCs may converge at the level of
Raf-1 for activation of ERKs (26, 29, 31). In a parallel
study (32), we found that BCR-mediated activation of
ERK2 was incompletely blocked in PLC-g2–deficient
DT40 cells or in DT40 cells transfected with a dominant
negative form of Ras (Ras N17). A complete block of
ERK2 activation was seen in PLC-g2–deficient cells trans-
fected with Ras N17, indicating that both Ras- and PLC-
g2–regulated PKCs are involved in BCR-mediated ERK2
activation. Taken together, our data suggest that Syk is es-
sential for both Ras-dependent activation of ERK2 and the
PLC-g2– and PKC-dependent, Btk-regulated pathway
leading to ERK2 activation (Fig. 6). Lyn was reported to
play a negative role in ERK activation (33), and Lyn-defi-
cient DT40 cells showed augmented BCR-mediated PKC
activation (34), leading to the speculation that Lyn-defi-
cient DT40 cells have augmented ERK2 activation. The
fact that we did not detect augmented ERK2 activation in
Figure 5. ERK2, JNK1, and p38 MAPK
have different requirements for PMA-
depletable PKCs. Cells (5 3 106/sample) were
incubated with PMA (100 ng/ml), the inac-
tive derivative 4a-phorbol (100 ng/ml), or
DMSO solvent vehicle control for 24 h be-
fore anti-IgM stimulation. Cell lysates (5 3
106/sample) were then prepared, and
ERK2, JNK1, and p38 MAPK activation
was measured as described in the legends to
Figs. 1–3, except that 12% SDS-PAGE was
used in all cases.1303 Jiang et al.
Lyn-deficient cells may reflect different roles of Lyn and/or
involvement of different PKCs for ERK activation at dif-
ferent stages of B cell development. Interestingly, a novel
PKC isoform, PKCm, which coprecipitates with both Syk
and PLC-g1/2 (35), showed the same pattern of BCR-
mediated activation as did ERK2. PKCm was activated in
wild-type and Lyn-deficient DT40 cells but not in Syk-
deficient DT40 cells, and was only partially activated in
Btk-deficient cells. Furthermore, PKCm is both calcium
independent and PMA inducible, suggesting that PKCm
may participate directly in the activation of ERK2 upon
BCR ligation. A possible role of PKCm in MAPK signaling
would not be surprising since other novel PKC isoforms
are also capable of activating ERKs (36). Further studies are
required to elucidate the precise role of PKCm and other
PKC isoforms in BCR-mediated ERK2 activation.
Both JNK and p38 MAPK are preferentially activated by
inflammatory cytokines and cellular stresses instead of clas-
sic mitogenic stimuli (37, 38). The JNK activation pathway
is well studied, and Rac1/cdc42, MEKK1, and MKK4/
MKK7 contribute to JNK activation (39–41). Consistent
with our finding that BCR-mediated JNK1 activation re-
quires both a calcium signal and PMA-sensitive PKCs,
JNK activation in a mouse B cell line also requires both
PMA and ionomycin (42). In T lymphocytes, JNK activa-
tion requires engagement of both the TCR and CD28 or
both PMA and ionomycin in contrast to the full activation
of ERK1 and ERK2 by either PMA or TCR engagement
alone (43). Our data also reveal that BCR-mediated JNK1
activation is dependent on Syk and Btk, which regulate
PLC-g2, but is not dependent on the Src family kinase Lyn
(Fig. 6). Consistent with our data, a recent study showed
that Syk but not Src family kinases in cooperation with Rac
led to enhanced JNK activation in Jurkat T cells (44). Sim-
ilarly, both a calcium signal and PKCs seem to account for
the requirement of Syk for JNK activation. Since Syk-
induced JNK activation is potentiated by anti-CD3, anti-
CD28, or PMA, it is likely that the requirement of Syk
could be at least partly due to a requirement for calcium
(44); the fact that JNK activation is not solely activated by
ionomycin or calcineurin, and that calcineurin does not
synergize with Rac to enhance JNK activation, suggests
that PKCs are the second component involved in JNK ac-
tivation by Syk (45). We also found that PLC-g2–deficient
cells exhibited impaired JNK1 activation and, interestingly,
a dominant negative Rac1 (Rac1 N17) blocked activation
of JNK1, suggesting a model where cooperation of PKCs
and Rac1 leads to JNK1 activation (32). Evidence from
studies of Jurkat cells also supports this model. A recent
study revealed that a particular PKC isoform, PKCu, but
not PKCa or PKCe, participated in JNK activation; more-
over, specific cooperation between calcineurin and PKCu
converged on Rac leading to potent JNK activation (45).
Btk is of interest since Btk is essential for BCR-mediated
JNK1 activation but not for p38 MAPK or ERK2 activa-
tion. A study using mast cells from Btk-defective mice also
had a similar result: the lack of Btk only led to a loss of
FceRI-mediated JNK1 activation but not ERKs or p38
MAPK activation (46). Recently, a novel MKK kinase,
MEKK4, which specifically activates the JNK pathway but
not ERKs or p38 MAPK, was identified (47); MEKK4 has
a Rac/cdc42 interacting binding motif, a putative pleck-
strin homology (PH) domain, and a proline-rich region
that could provide the binding site for the Src homology
(SH)3 domain. Since Btk has a PH domain, a proline-rich
region, and SH2 and SH3 domains (48, 49), and since PH
domains can interact with PKCs (50), one attractive model
is that the interaction of Btk and MEKK4 defines the spec-
ificity of JNK signaling pathway (Fig. 6).
Less is known concerning the p38 MAPK signaling
pathway. p38 MAPK can be turned on independently of
JNKs since both MKK3 and MKK6 activate p38 MAPK
specifically (51, 52); however, the upstream activators of
MKK3 and MKK6 are still not fully defined. One potential
upstream activator may be a STE20/PAK homologue such
as Mst1 (53, 54). It is also not clear at what point p38
MAPK and JNK pathways diverge and what the mecha-
nisms are that lead to specific activation of p38 MAPK ver-
sus JNKs. Although our data do not entirely solve the puz-
zle, they do indicate that in DT40 cells p38 MAPK is
activated by BCR ligation via a distinct pathway from
JNK1: either Syk or Lyn is sufficient and Btk is not re-
quired for BCR-mediated p38 MAPK activation; in con-
trast, anti-IgM–induced JNK activation requires both Syk
and Btk but not Lyn (Fig. 6). BCR-mediated p38 MAPK
was only partially affected in Syk-deficient (Fig. 3 A) and
PKC-depleted cells (Fig. 5 C), again suggesting that both
Figure 6. A model for the different pathways leading to BCR-medi-
ated ERK2, JNK1, and p38 MAPK activation in DT40 cells. BCR cross-
linking leads to activation of the protein tyrosine kinases Lyn, Syk, and
Btk. Loss of either Syk or Btk leads to abrogation of calcium mobiliza-
tion, although only Syk is essential for PLC-g2 phosphorylation. PLC-g2
phosphorylation leads to calcium mobilization and PKC activation. Syk
but not Lyn is essential for BCR-mediated ERK2 activation and Btk may
function as a regulator of the ERK2 pathway since partial BCR-mediated
ERK2 activation is observed in Btk-deficient cells. The requirement for
Syk and Btk may reflect the requirement of PKCs for ERK2 activa-
tion. In contrast, BCR-mediated JNK1 activation depends on both Syk
and Btk but not Lyn, via a calcium- and PKC-dependent pathway. For
p38 MAPK, a distinct pathway is used for BCR-mediated activation of
p38 MAPK, since either Syk or Lyn is sufficient for BCR-mediated p38
MAPK activation. A Lyn-dependent pathway for p38 MAPK activation
may not require PKCs, whereas the Syk-dependent pathway does. Nei-
ther a calcium signal nor PMA-depletable PKCs are absolutely essential
for BCR-mediated p38 MAPK activation, although PMA-insensitive
PKCs may be required.1304 Differential Activation of Distinct MAP Kinases via the B Cell Receptor
Syk- and Lyn-dependent signals may contribute to p38
MAPK activation independently (Fig. 6). Just how the two
p38 MAPK signaling pathways interact and are regulated
remains to be determined.
Activation of MAPK family members may contribute to
the induction of programmed cell death or apoptosis. Apop-
tosis plays an important role in B cell development and the
generation of immune responses (55), and DT40 cells un-
dergo apoptosis upon BCR cross-linking. Our studies us-
ing the B104 B cell line show that p38 MAPK plays a role
in BCR-mediated apoptosis (56) and that activation of
JNK1 correlates with induction of cell death (18). In DT40
cell lines, BCR-mediated apoptosis is blocked in both Syk-
and Btk-deficient cells (57, 58), which also do not activate
JNK1; cells in which JNK1 is activated via the BCR (wild-
type and Lyn-deficient DT40 cells) also undergo apoptosis
(53); in addition, BAPTA-AM blocks both apoptosis and
JNK1 activation but not BCR-mediated ERK2 or p38
MAPK activation (Fig. 4 and data not shown). Thus, acti-
vation of JNK1 correlated best with the induction of apop-
tosis in DT40 cells. We also tested the role of p38 MAPK
in apoptosis and found that only a relatively high dose of
SB203580 (20 mM), a highly specific and cell-permeable
inhibitor of p38 MAPK, completely blocked BCR-medi-
ated apoptosis in DT40 cells (Jiang, A., A. Craxton, and
E.A. Clark, unpublished data). Thus, it is not presently
clear whether JNK1 alone or in cooperation with p38
MAPK may be needed to activate a death program in
DT40 cells. Further work with knockout mice and primary
B cells is needed to assess the function of distinct MAPKs in
B cell development and activation.
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